Literature DB >> 25052964

Venous thromboembolism (VTE): risk assessment in hospitalized patients.

Quratulain Soomro1, Nailla Yousuf2, Afsar Ali Bhutto1, Hakim Ali Abro3, Aijaz Ahmed Memon1.   

Abstract

OBJECTIVE: To determine the number of hospitalized patients at risk for developing venous thromboembolism (VTE) / deep vein thrombosis (DVT), identifying the most common risk factor and to document the use of thromboprophylaxis. STUDY
DESIGN: Observational and cross-sectional study. PLACE AND DURATION OF STUDY: Chandka Medical College Hospital, Larkana, from October to December 2011.
METHODOLOGY: A total of 170 patients underwent this study and these included 51 (30%) from general medical, and 119 (70%) from surgical units. Inclusion and exclusion criteria were defined and data was collected on printed format. VTE risk assessment was done according to Caprini Model and criteria defined by the American College of Chest Physicians- ACCP.
RESULTS: Out of 170 patients, 91 were male and 79 female with mean age of 39 ± 16 years. According to ACCP criteria for VTE risk assessment, 20% (n=34) patients were identified to be at low risk, 20% (n=34) at moderate risk, 47.65% (n=81) at high risk and 12.35% (n=21) at very high risk of developing VTE. The commonest risk factor significantly identified was immobility (54.7%, p < 0.005), followed by advancing age (41.17%, p < 0.005) and obesity (18.23%). The most common risk factor in all types of surgical patients was anaesthesia for more than 45 minutes 82.35% (n=98/119) and in medical patients advancing age 45% (n=23/51). Only 6 (3.5%) patients received thromboprophylaxis, all were surgical patients of very high-risk category.
CONCLUSION: Majority of studied hospitalized patients were at high risk of developing VTE. Immobility was the commonest risk factor for developing VTE, followed by advancing age and obesity. Very few hospitalized patients actually received thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052964     DOI: 07.2014/JCPSP.455458

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  6 in total

1.  Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients.

Authors:  Paul J Grant; M Todd Greene; Vineet Chopra; Steven J Bernstein; Timothy P Hofer; Scott A Flanders
Journal:  Am J Med       Date:  2015-11-06       Impact factor: 4.965

2.  Predictive factors for effectiveness and safety of enoxaparin for total knee arthroplasty in aged Japanese patients: a retrospective review.

Authors:  Akihiro Sonoda; Yuki Kondo; Yasuhiro Tsuneyoshi; Yoshitaka Iwashita; Shoji Nakao; Kazuhisa Ishida; Kentaro Oniki; Junji Saruwatari; Tetsumi Irie; Yoichi Ishitsuka
Journal:  J Pharm Health Care Sci       Date:  2017-01-18

3.  Risk Factors for Venous Thromboembolism in Hospitalized Patients in the Chinese Population.

Authors:  Chunling Wang; Fuping Cui; Junqiu Li; Xiangzhi Yuan; Jia Wang; Liyun Liu; Mingxiao Wang
Journal:  Open Life Sci       Date:  2018-04-10       Impact factor: 0.938

4.  Incidence of thromboembolism and thromboprophylaxis in medical patients admitted to specialized hospital in Ethiopia using Padua prediction score.

Authors:  Mulugeta Asmamaw; Wubet Hungnaw; Achenef Motbainor; Hanan Muzeyin Kedir; Tamrat Assefa Tadesse
Journal:  SAGE Open Med       Date:  2022-02-21

5.  Evaluation of venous thromboembolism (VTE) risk assessment and thrombo-prophylaxis practices in hospitalized medical and surgical patients at Aga Khan Hospital Dar es Salaam: single-centre retrospective study.

Authors:  Allyzain Ismail; Nikhil Jadawji; Philip Adebayo; Ahmed Jusabani; Kamran Hameed; Ali Akbar Zehri; Willy Kiviri; Athar Ali
Journal:  Pan Afr Med J       Date:  2022-06-29

6.  Epidemiological status and risk factors of deep vein thrombosis in patients with femoral neck fracture.

Authors:  Tianhua Li; Chenhao Dou; Shuhong Yang; Qian Geng; Qing Lu; Yahui Zhang; Jingjing Yu; Fang Hu; Junqin Ding
Journal:  J Orthop Surg Res       Date:  2022-01-22       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.